IFHA
Institut für Hanfanalytik

Christian Fuczik -
Chemisches Labor GmbH
Gerhardusgasse 25/3.OG 1200 Wien
E-Mail: info@hanfanalytik.at
Tel.: +43 660 867 00 63
www.hanfanalytik.at

Certificate of Analysis Cannabinoids

Description I:	UT Nano FS 1:1:1	Client:	UNIQUE THERAPEUTICS INC.
Sample date:	———————	Sample ID:	A2800323
Bloomday:	———————	Sample material:	water soluble
Description II:	———————		
Further information:	———————		

Abbr.	Cannabinoids Advanced	Result	Unit
T-CBD	**Total Cannabidiol (CBD + CBDA)**	**0,67**	**% (w/w)**
CBD	Cannabidiol	0,67	% (w/w)
CBDA	Cannabidiolic acid	ND**	% (w/w)
T-THC	**Total Tetrahydrocannabinol (THC + THCA)**	**0,68**	**% (w/w)**
D9THC	D9-Tetrahydrocannabinol	0,68	% (w/w)
THCA	Tetrahydrocannabinolic acid	ND**	% (w/w)
D8THC	D8-Tetrahydrocannabinol	ND**	% (w/w)
T-CBG	**Total Cannabigerol (CBG + CBGA)**	**0,78**	**% (w/w)**
CBG	Cannabigerol	0,78	% (w/w)
CBGA	Cannabigerolic acid	ND**	% (w/w)
CBN	Cannabinol	ND**	% (w/w)
CBNA	Cannabinolic Acid	ND**	% (w/w)
CBC	Cannabichromene	ND**	% (w/w)
CBCA	Cannabichromenic Acid	ND**	% (w/w)
CBDV	Cannabidivarin	ND**	% (w/w)
CBDVA	Cannabidivarinic Acid	ND**	% (w/w)
CBL	Cannabicyclol	ND**	% (w/w)
CBLA	Cannabicyclolic Acid	ND**	% (w/w)
THCV	Tetrahydrocannabivarin	ND**	% (w/w)
THCVA	Tetrahydrocannabivarinic Acid	ND**	% (w/w)
9R-HHC	9R-Hexahydrocannabinol	ND**	% (w/w)
9S-HHC	9S-Hexahydrocannabinol	ND**	% (w/w)
HHCP	Hexahydrocannabiphorol*	ND**	% (w/w)
H4CBD	Tetrahydrocannabidiol*	ND**	% (w/w)

Sample received: 15/01/2025 - 600 g

Head of Laboratory Services

Ing. Christian Fuczik, Chemist
Analysis reviewed - last changes: 17/01/2025 at 10:38

Footnote:
*) Stereoisomeres results on request. **) ND =not detectable. The measured value was below the limit of detection of 0.01 % or 100 mg/kg.
The expected measurement uncertainty varies with substance and concentration and can be assumed to be a maximum of 10 %.
For the calculations of the equivalent sums, the respective acid forms were multiplied by the factor 0.877 or 0.878 to conclude the equivalent amount of the neutral form.
Analytical methods: HPLC-DAD, GC-FID and GC mass spectrometry (European Pharmacopoeia: 2.2.28, 2.2.29 and 2.2.43).